Huang C, Kaur A, Ji L, Tian H, Webster K, Li W
Gene Ther. 2024; 31(11-12):587-593.
PMID: 39333408
PMC: 11720169.
DOI: 10.1038/s41434-024-00491-9.
Huang C, Waduge P, Kaur A, Tian H, Weng C, Stout J
Int J Mol Sci. 2024; 25(17).
PMID: 39273454
PMC: 11394726.
DOI: 10.3390/ijms25179507.
Fu Y, Zhang Z, Webster K, Paulus Y
Biomolecules. 2024; 14(3).
PMID: 38540673
PMC: 10968528.
DOI: 10.3390/biom14030252.
Pereira D, Maturi R, Akita K, Mahesh V, Bhisitkul R, Nishihata T
Eye (Lond). 2023; 38(6):1140-1148.
PMID: 38036609
PMC: 11009322.
DOI: 10.1038/s41433-023-02848-7.
Huang C, Ji L, Kaur A, Tian H, Waduge P, Webster K
Biomedicines. 2023; 11(7).
PMID: 37509549
PMC: 10377229.
DOI: 10.3390/biomedicines11071910.
Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.
Cheng A, Joshi S, Banoub R, Saddemi J, Chalam K
Cureus. 2023; 15(6):e40100.
PMID: 37425528
PMC: 10328548.
DOI: 10.7759/cureus.40100.
Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides.
Nhan N, Maidana D, Yamada K
Cells. 2023; 12(7.
PMID: 37048144
PMC: 10093283.
DOI: 10.3390/cells12071071.
Targeting angiogenesis in oncology, ophthalmology and beyond.
Cao Y, Langer R, Ferrara N
Nat Rev Drug Discov. 2023; 22(6):476-495.
PMID: 37041221
DOI: 10.1038/s41573-023-00671-z.
METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial-mesenchymal transition.
Wang Y, Chen Y, Liang J, Jiang M, Zhang T, Wan X
J Mol Cell Biol. 2023; 15(3).
PMID: 36945110
PMC: 10603769.
DOI: 10.1093/jmcb/mjad005.
Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans.
Wada I, Nakao S, Fukuda Y, Shiose S, Takeda A, Kannan R
Graefes Arch Clin Exp Ophthalmol. 2023; 261(8):2189-2197.
PMID: 36869890
DOI: 10.1007/s00417-023-06018-z.
Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models.
Lee S, Kim S, Jo D, Cho C, Kim S, Kang D
Commun Med (Lond). 2022; 1:58.
PMID: 35602228
PMC: 9053257.
DOI: 10.1038/s43856-021-00059-3.
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.
Hernandez-Jimenez M, Martin-Vilchez S, Ochoa D, Mejia-Abril G, Roman M, Camargo-Mamani P
Mol Ther Nucleic Acids. 2022; 28:124-135.
PMID: 35402075
PMC: 8938885.
DOI: 10.1016/j.omtn.2022.03.005.
Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options.
Fernandes A, Zielinska A, Sanchez-Lopez E, Dos Santos T, Garcia M, Silva A
Int J Mol Sci. 2022; 23(5).
PMID: 35269743
PMC: 8910030.
DOI: 10.3390/ijms23052592.
Discovering the Potential of Natural Antioxidants in Age-Related Macular Degeneration: A Review.
Wong K, Nam H, Lew S, Naidu M, David P, Kamalden T
Pharmaceuticals (Basel). 2022; 15(1).
PMID: 35056157
PMC: 8777838.
DOI: 10.3390/ph15010101.
Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.
Ji L, Waduge P, Wan W, Tian H, Li J, Zhang J
FEBS J. 2022; 289(12):3521-3534.
PMID: 35038348
PMC: 9232851.
DOI: 10.1111/febs.16356.
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.
Ghanchi F, Bourne R, Downes S, Gale R, Rennie C, Tapply I
Eye (Lond). 2022; 36(6):1154-1167.
PMID: 34974541
PMC: 9151779.
DOI: 10.1038/s41433-021-01766-w.
Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD).
Sarkar A, Junnuthula V, Dyawanapelly S
Int J Mol Sci. 2021; 22(19).
PMID: 34638935
PMC: 8508687.
DOI: 10.3390/ijms221910594.
Pipeline therapies for neovascular age related macular degeneration.
Arepalli S, Kaiser P
Int J Retina Vitreous. 2021; 7(1):55.
PMID: 34598731
PMC: 8485527.
DOI: 10.1186/s40942-021-00325-5.
Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.
Hussain R, Shaukat B, Ciulla L, Berrocal A, Sridhar J
Drug Des Devel Ther. 2021; 15:2653-2665.
PMID: 34188445
PMC: 8232378.
DOI: 10.2147/DDDT.S295223.
DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously.
Beckmann R, Jensen K, Fenn S, Speck J, Krause K, Meier A
Nat Commun. 2021; 12(1):708.
PMID: 33514724
PMC: 7846786.
DOI: 10.1038/s41467-021-20949-3.
